Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House hearing on HB 117: sponsors seek flexibility so state law can track FDA changes on biosimilar interchangeability
Summary
HB 117 would allow New Hampshire to follow future FDA changes regarding interchangeability of biologics and biosimilars so pharmacists can implement federal guidance promptly; insurers and manufacturers testified with differing views on patient safety and market effects.
Representative Michael Leon introduced HB 117 to the House Committee on Health, Human Services and Elderly Affairs, describing the bill as narrow: it would allow state law to adapt to federal changes if the Food and Drug Administration alters regulatory pathways for designating biosimilars as interchangeable with originator biologics. Leon and other supporters said the goal is to avoid a state statute becoming outdated if the FDA adopts new scientific standards that obviate the historical need for in‑patient switching studies.
Sponsor testimony stressed the potential for cost savings and improved access. Leon described how biosimilars can reduce out‑of‑pocket costs for patients…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
